A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a clinical-stage biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. We’re doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways—all with one goal: transforming the lives of millions of patients with skin diseases.

Dermavant Voices: Patient-Focused Innovation

“The ability to transform lives”

Todd Zavodnick
Chief Executive Officer

“A passion for helping people”

Philip M Brown, MD, JD
Chief Medical Officer

“Fundamentally changing the lives of patients”

David Rubenstein, MD, PhD
Chief Scientific Officer

DERMAVANT. Innovating. Pioneering. Transforming.

We Will Transform Dermatology.

VIEW CORPORATE FACT SHEET

Latest News

January 15, 2022

Dermavant Presents New Patient Satisfaction Data f ...

January 7, 2022

Dermavant to Present New Data from Phase 3 PSOARIN ...

December 9, 2021

Dermavant Announces Publication of PSOARING 1  ...